Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine

Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine

Background: Azacitidine (AZA) is the standard treatment for patients with high-risk myelodysplastic syndromes (MDS). The impact of skeletal muscle depletion (SMD), which is associated with outcomes of hematological malignancies, on the clinical course of MDS patients treated with AZA was investigate...

Descripció completa

Dades bibliogràfiques
Autors principals: Eri Takada, Nobuhiko Nakamura, Yuto Kaneda, Kenji Fukuno, Shin Lee, Kei Fujita, Tetsuji Morishita, Yoshikazu Ikoma, Takuro Matsumoto, Hiroshi Nakamura, Junichi Kitagawa, Nobuhiro Kanemura, Senji Kasahara, Takeshi Hara, Hisashi Tsurumi, Masahito Shimizu
Format: Article
Idioma:English
Publicat: MDPI AG 2024-02-01
Col·lecció:Hematology Reports
Matèries:
myelodysplastic syndrome
azacitidine
skeletal muscle depletion
hematological toxicity
Accés en línia:https://www.mdpi.com/2038-8330/16/1/12

Internet

https://www.mdpi.com/2038-8330/16/1/12

Ítems similars